1,036 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by HB Wealth Management LLC

Posted by on Apr 1st, 2023

HB Wealth Management LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,036 shares of the company’s stock, valued at approximately $423,000.

Several other institutional investors also recently modified their holdings of the business. Pine Haven Investment Counsel Inc grew its stake in shares of IDEXX Laboratories by 3.1% in the fourth quarter. Pine Haven Investment Counsel Inc now owns 758 shares of the company’s stock worth $309,000 after purchasing an additional 23 shares during the last quarter. Carolinas Wealth Consulting LLC boosted its position in IDEXX Laboratories by 28.7% during the third quarter. Carolinas Wealth Consulting LLC now owns 130 shares of the company’s stock valued at $42,000 after acquiring an additional 29 shares during the last quarter. Anderson Hoagland & Co. boosted its position in IDEXX Laboratories by 0.3% during the third quarter. Anderson Hoagland & Co. now owns 11,163 shares of the company’s stock valued at $3,637,000 after acquiring an additional 31 shares during the last quarter. Washington Trust Advisors Inc. boosted its position in IDEXX Laboratories by 11.5% during the third quarter. Washington Trust Advisors Inc. now owns 301 shares of the company’s stock valued at $98,000 after acquiring an additional 31 shares during the last quarter. Finally, Berkshire Bank boosted its position in IDEXX Laboratories by 2.0% during the third quarter. Berkshire Bank now owns 1,609 shares of the company’s stock valued at $524,000 after acquiring an additional 31 shares during the last quarter. Institutional investors own 87.90% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, SVP Kathy V. Turner sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $505.04, for a total transaction of $505,040.00. Following the sale, the senior vice president now owns 6,941 shares of the company’s stock, valued at approximately $3,505,482.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, SVP Kathy V. Turner sold 1,000 shares of the business’s stock in a transaction on Thursday, February 9th. The shares were sold at an average price of $505.04, for a total value of $505,040.00. Following the completion of the transaction, the senior vice president now directly owns 6,941 shares in the company, valued at approximately $3,505,482.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Kathy V. Turner sold 2,000 shares of the company’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the transaction, the senior vice president now owns 7,380 shares of the company’s stock, valued at $3,723,874.20. The disclosure for this sale can be found here. Insiders own 2.06% of the company’s stock.

IDEXX Laboratories Stock Up 1.3 %

IDXX opened at $500.08 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 1.14. IDEXX Laboratories, Inc. has a 1-year low of $317.06 and a 1-year high of $560.92. The company has a market capitalization of $41.46 billion, a PE ratio of 62.28, a PEG ratio of 2.83 and a beta of 1.18. The firm’s 50 day simple moving average is $484.34 and its two-hundred day simple moving average is $423.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last issued its quarterly earnings data on Monday, February 6th. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.92 by $0.13. IDEXX Laboratories had a net margin of 20.17% and a return on equity of 124.51%. The business had revenue of $828.60 million during the quarter, compared to analysts’ expectations of $820.91 million. During the same period last year, the company posted $1.89 EPS. The business’s revenue was up 3.4% on a year-over-year basis. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 9.57 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on IDXX. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $525.00 to $550.00 and gave the company an “overweight” rating in a research report on Tuesday, February 7th. The Goldman Sachs Group upped their price objective on shares of IDEXX Laboratories from $465.00 to $530.00 and gave the company a “buy” rating in a report on Wednesday, January 25th. Barclays upped their price objective on shares of IDEXX Laboratories from $582.00 to $590.00 and gave the company an “overweight” rating in a report on Wednesday, February 8th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $543.00 to $590.00 and gave the company an “overweight” rating in a report on Thursday, March 23rd. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $520.63.

IDEXX Laboratories Company Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.

Recommended Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.